In this study, as shown in Figures 5 and 8, compared with model group, Nrf2 and its target genes (HO-1, NQO1, GST, and r-GCS) were up-regulated by TFCH treatments in vivo and in vitro, demonstrating the therapeutic mechanism of TFCH against NASH was related with Nrf-ARE signaling. This evidence concerns the gene HMOX1 and metabolic dysfunction-associated steatohepatitis.